ReviewOrphanet journal of rare diseases2008
Primary intestinal lymphangiectasia (Waldmann's disease).
Review in Orphanet journal of rare diseases, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 112 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
112 citing papers in PubMed, 285 citations in OpenAlex.
- Feline chronic diarrhea: causes and nutritional management.Veterinary and animal science · 2026Review
- Reproductive considerations in patients undergoing treatment for complex lymphatic anomalies.Journal of vascular anomalies · 2026Article
- Intestinal ultrasound in primary intestinal lymphangiectasia (Waldmann's disease): a PRISMA-ScR scoping review with an illustrative adult case.Journal of ultrasound · 2026Review
- Human inherited RORγT deficiency encompasses genetic heterogeneity, T cell deficiency, and clinical homogeneity.medRxiv : the preprint server for health sciences · 2026Article
- Peripheral Lymphatic Shunts for Protein-Losing Enteropathy in a Child with THSD1 Mutation: A Case Report.Archives of plastic surgery · 2026Article
- Primary Intestinal Lymphangiectasia as a cause of secondary combined immunodeficiency: case study and literature review.Clinical immunology communications · 2026Article
- Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions.International journal of molecular sciences · 2026Review
- Abdominal Lymphatic Malformations Presenting as Protein-Losing Enteropathy.ACG case reports journal · 2026Article
- Intestinal Lymphangioma With Extensive Secondary Lymphangiectasia Causing Life-Threatening Hemorrhage: First Case Requiring Small Bowel Transplantation.Case reports in pathology · 2026Article
- Successful Early Therapy With Sirolimus for an Infant With Primary Intestinal Lymphangiectasia.Case reports in pediatrics · 2026Article
- Primary intestinal lymphangiectasia in a 5-month-old boy.Clinical endoscopy · 2026Article
- Immunodeficiencies in Adults: Key Considerations for Diagnosis and Management.Clinical reviews in allergy & immunology · 2025Review
- The use of octreotide in pediatric patients: Practical applications for gastrointestinal disorders and beyond: A narrative review.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2025Review
- Intestinal Lymphangiectasia: A Rare Etiology of Gastrointestinal Bleeding.Clinical case reports · 2025Article
- Primary intestinal lymphangiectasia: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).Orphanet journal of rare diseases · 2025Review
- Elusive Edematous Primary Intestinal Lymphangiectasia in an Adult Patient Presenting With New Onset of Protein-Losing Enteropathy.ACG case reports journal · 2025Article
- Edible Safety Evaluation ofFoods (Basel, Switzerland) · 2025Article
- Elderly Onset Primary Intestinal Lymphangiectasia-A Rare Case.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Rapid desensitization for human serum albumin (GrifolsPostepy dermatologii i alergologii · 2024Article
- A novel mutation in the SLCO2A1 gene presenting as persistent hypoproteinaemia and refractory iron deficiency anaemia due to chronic enteropathy: a case report.BMC pediatrics · 2024Article
52 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary intestinal lymphangiectasia (PIL) is a rare disorder characterized by dilated intestinal lacteals resulting in lymph leakage into the small bowel lumen and responsible for protein-losing enteropathy leading to lymphopenia, hypoalbuminemia and hypogammaglobulinemia. PIL is generally diagnosed before 3 years of age but may be diagnosed in older patients. Prevalence is unknown. The main symptom is predominantly bilateral lower limb edema. Edema may be moderate to severe with anasarca and includes pleural effusion, pericarditis or chylous ascites. Fatigue, abdominal pain, weight loss, inability to gain weight, moderate diarrhea or fat-soluble vitamin deficiencies due to malabsorption may also be present. In some patients, limb lymphedema is associated with PIL and is difficult to distinguish lymphedema from edema. Exsudative enteropathy is confirmed by the elevated 24-h stool alpha1-antitrypsin clearance. Etiology remains unknown. Very rare familial cases of PIL have been reported. Diagnosis is confirmed by endoscopic observation of intestinal lymphangiectasia with the corresponding histology of intestinal biopsy specimens. Videocapsule endoscopy may be useful when endoscopic findings are not contributive. Differential diagnosis includes constrictive pericarditis, intestinal lymphoma, Whipple's disease, Crohn's disease, intestinal tuberculosis, sarcoidosis or systemic sclerosis. Several B-cell lymphomas confined to the gastrointestinal tract (stomach, jejunum, midgut, ileum) or with extra-intestinal localizations were reported in PIL patients. A low-fat diet associated with medium-chain triglyceride supplementation is the cornerstone of PIL medical management. The absence of fat in the diet prevents chyle engorgement of the intestinal lymphatic vessels thereby preventing their rupture with its ensuing lymph loss. Medium-chain triglycerides are absorbed directly into the portal venous circulation and avoid lacteal overloading. Other inconsistently effective treatments have been proposed for PIL patients, such as antiplasmin, octreotide or corticosteroids. Surgical small-bowel resection is useful in the rare cases with segmental and localized intestinal lymphangiectasia. The need for dietary control appears to be permanent, because clinical and biochemical findings reappear after low-fat diet withdrawal. PIL outcome may be severe even life-threatening when malignant complications or serous effusion(s) occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.